Recipharm installs dedicated production line for prostate cancer depot

By Dan Stanton contact

- Last updated on GMT

Image: iStock/naruedom
Image: iStock/naruedom

Related tags: Manufacturing, Cancer, Pharmaceutical formulation

Recipharm has installed a dedicated production line to make prostate cancer drug Liproca Depot for Swedish pharma firm LIDDS AB.

Contract manufacturing organisation (CMO) Recipharm commenced negotiations to make LIDDS’ Liproca Depot in April 2015​, and began developing a process for the commercial production the modified-release cancer candidate later that year.

And yesterday Recipharm announced a dedicated manufacturing line adapted for GMP production has been established at its facility in Solna, Sweden.

“This was a very challenging project as it required the purchase, installation and qualification of several pieces of equipment,”​ Torkel Gren, general manager of the facility told in-Pharmatechnologist.com.

“Some of this equipment has not been used in the pharma industry before. Recipharm has experience in setting up new types of technology for GMP manufacture so this was a project that we were well suited for.”

In total seven pieces of new equipment have been installed to make Liproca Depot, Gren revealed though he could not comment on either the cost of the project or which company footed the bill.

Liproca Depot comprises of a modified-release formulation of 2-hydroxyflutamid, prepared as a paste, delivered in a pre-filled container/syringe, which also acts as mixing equipment of the paste prior to injection.

Using LIDDS’ NanoZolid technology, the local administration could offer advantages over current prostate cancer treatments including fewer side effects, reduced dosing frequency and improved patient compliance.

The manufacturing process consists of three main stages: nanocrystal activation with heat, micronisation and drug dispersion, and drug encapsulation by hydration and isotatic pressure.

According to Gren, line could be used for future LIDDS’ pharmaceutical formulations based on the NanoZolid technology.

Related news

Show more

Related products

show more

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars